AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30796919 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized Physical Therapy (SPT)
Number of subjects: 96
Study 30796919 — intervention group
Group type: COMPARATOR
Intervention: Regular Physical Therapy (RPT)
Number of subjects: 96
Study 27631821 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term dual antiplatelet therapy (DAPT) (6 months or less)
Number of subjects: 1661
Study 27631821 — intervention group
Group type: COMPARATOR
Intervention: Prolonged dual antiplatelet therapy (DAPT) (12 months or more)
Number of subjects: 1661
Study 26445777 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol
Number of subjects: 35
Study 26445777 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.1% sodium chloride solution (hypertonic saline)
Number of subjects: 35
Study 26445777 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 35
Study 23706155 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate feedback on alcohol consumption and access to an online intervention (Down Your Drink)
Number of subjects: 1472
Study 23706155 — intervention group
Group type: COMPARATOR
Intervention: Delayed feedback and access to Down Your Drink after completion of follow‐up data at three months
Number of subjects: 1472
Study 21537493 — intervention group
Group type: COMPARATOR
Intervention: p-synephrine (50 mg)
Number of subjects: 10
Study 21537493 — intervention group
Group type: COMPARATOR
Intervention: p-synephrine (50 mg) + naringin (600 mg)
Number of subjects: 10
Study 21537493 — intervention group
Group type: COMPARATOR
Intervention: p-synephrine (50 mg) + naringin (600 mg) + hesperidin (100 mg)
Number of subjects: 10
Study 21537493 — intervention group
Group type: COMPARATOR
Intervention: p-synephrine (50 mg) + naringin (600 mg) + hesperidin (1000 mg)
Number of subjects: 10
Study 21537493 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 10
Study 19616143 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week individualized home-based exercise intervention (n=46)
Number of subjects: 88
Study 19616143 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group (n=42)
Number of subjects: 88
Study 17162192 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (40 mg/kg/day, 3 days)
Number of subjects: 60
Study 17162192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17162192 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 60
Study 15167086 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-infant home-visiting services (0 to 18 months of weekly visits)
Number of subjects: 63
Study 11388520 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone-tipped tube with new bevel design
Number of subjects: 30
Study 11388520 — intervention group
Group type: COMPARATOR
Intervention: Wire-reinforced polyvinyl chloride tube with standard bevel
Number of subjects: 30
Study 9671343 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (15-60 mg/day)
Number of subjects: 133
Study 9671343 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20-40 mg/day)
Number of subjects: 133
Study 9671343 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 133
Study 9671343 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 133
Study 8071511 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental nasal oxygen (2 l/min)
Number of subjects: 100
Study 8071511 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 100
Study 8071511 — intervention group
Group type: COMPARATOR
Intervention: Room air (elective procedures)
Number of subjects: 100
Study 2647817 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC (30 U over 5 min)
Number of subjects: 231
Study 2647817 — intervention group
Group type: COMPARATOR
Intervention: Heparin (5,000 IU in a bolus injection)
Number of subjects: 231
Study 2647817 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 231
Study 2647817 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 231
Study 2647817 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC (anterior infarction subgroup)
Number of subjects: 231
Study 2647817 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC (inferior infarction subgroup)
Number of subjects: 231
Study 2647817 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 231
Study 4426706 — intervention group
Group type: EXPERIMENTAL
Intervention: C14‐S5 strain with varying doses
Number of subjects: 32
Study 4426706 — intervention group
Group type: EXPERIMENTAL
Intervention: C14‐S5 strain (10^9 organisms)
Number of subjects: 32
Study 4426706 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated controls
Number of subjects: 32
Study 31718249 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory control
Number of subjects: 112
Study 31718249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive theory of mind
Number of subjects: 112
Study 31718249 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional theory of mind
Number of subjects: 112
Study 31718249 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological tasks requiring high inhibitory control
Number of subjects: 112
Study 31718249 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological tasks not requiring high inhibitory control
Number of subjects: 112
Study 31339677 — intervention group
Group type: EXPERIMENTAL
Intervention: TAF-based group (DTG + FTC + TAF)
Number of subjects: 1053
Study 31339677 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF-based group (DTG + FTC + TDF)
Number of subjects: 1053
Study 31339677 — intervention group
Group type: COMPARATOR
Intervention: Standard-care group (TDF-FTC-efavirenz)
Number of subjects: 1053
Study 31339677 — intervention group
Group type: EXPERIMENTAL
Intervention: TAF-based group
Number of subjects: 1053
Study 31339677 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF-based group
Number of subjects: 1053
Study 31339677 — intervention group
Group type: COMPARATOR
Intervention: Standard-care group
Number of subjects: 1053
Study 31339677 — intervention group
Group type: EXPERIMENTAL
Intervention: DTG-containing regimens
Number of subjects: 1053
Study 28182218 — intervention group
Group type: COMPARATOR
Intervention: Motivational intervention
Number of subjects: 560
Study 28182218 — intervention group
Group type: COMPARATOR
Intervention: Reduction intervention
Number of subjects: 560
Study 26061762 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% maltodextrin solution (CHO)
Number of subjects: 11
Study 26061762 — intervention group
Group type: COMPARATOR
Intervention: Noncaloric placebo (PLA)
Number of subjects: 11
Study 23863810 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone (PGZ; 45 mg/day)
Number of subjects: 441
Study 23863810 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 441
Study 23863810 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher final glucose tolerance status (NGT > IGT > T2DM)
Number of subjects: 441
Study 21688068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 0
Study 21688068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 0
Study 21688068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19519298 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 0
Study 19519298 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0
Study 19519298 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib or Erlotinib in combination with chemotherapy
Number of subjects: 0
Study 19519298 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression free survival
Number of subjects: 0
Study 19519298 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival and quality of life
Number of subjects: 0
Study 16306168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 97
Study 16306168 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 97
Study 16306168 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 97
Study 12700713 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 246
Study 12700713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 10831812 — intervention group
Group type: COMPARATOR
Intervention: Osteoarthritic group
Number of subjects: 20
Study 10831812 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-symptomatic group
Number of subjects: 20
Study 9412258 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of propofol (5‐8 mg/kg.h)
Number of subjects: 239
Study 9412258 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane in a maximum concentration of 0.6 vol.% in 70% nitrous oxide and 30% oxygen
Number of subjects: 239
Study 9412258 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol induction followed by short duration of general anaesthesia
Number of subjects: 239
Study 9412258 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion regimen
Number of subjects: 239
Study 7682167 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac dispersible
Number of subjects: 129
Study 7682167 — intervention group
Group type: COMPARATOR
Intervention: Conventional enteric-coated tablet of diclofenac sodium 50 mg orally, thrice daily
Number of subjects: 129
Study 3806153 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medication (thiazide diuretic and propranolol if needed)
Number of subjects: 45
Study 3806153 — intervention group
Group type: COMPARATOR
Intervention: Chinese herbal preparation (mixture of 12 herbs)
Number of subjects: 45
Study 31122860 — intervention group
Group type: EXPERIMENTAL
Intervention: NBP608
Number of subjects: 823
Study 31122860 — intervention group
Group type: COMPARATOR
Intervention: Zostavax® (comparator)
Number of subjects: 823
Study 27771274 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) administered 3 times a day for 2 consecutive days, each cycle lasting 1 to 3 hours
Number of subjects: 64
Study 27771274 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (oxygen, early mobilization, a program of breathing exercises and diuretics)
Number of subjects: 64
Study 27771274 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 25494205 — intervention group
Group type: EXPERIMENTAL
Intervention: GTRB (green tea extract enriched rye bread)
Number of subjects: 55
Study 25494205 — intervention group
Group type: COMPARATOR
Intervention: Control rye bread
Number of subjects: 55
Study 23570299 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroxide bleaching gel Opalescence PF 20, treated 25 times for eight hours per day.
Number of subjects: 4
Study 23570299 — intervention group
Group type: COMPARATOR
Intervention: Control groups stored in distilled water for two months before testing.
Number of subjects: 4
Study 23570299 — intervention group
Group type: COMPARATOR
Intervention: Control groups for ADP and IBO.
Number of subjects: 4
Study 23570299 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroxide bleaching gel Opalescence PF 20.
Number of subjects: 4
Study 23570299 — intervention group
Group type: EXPERIMENTAL
Intervention: Electron microscopy analysis.
Number of subjects: 4
Study 22118569 — intervention group
Group type: COMPARATOR
Intervention: Control (wheat-fiber, n = 74)
Number of subjects: 367
Study 22118569 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g high-MW oat β-glucan (3H, n = 67)
Number of subjects: 367
Study 22118569 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g medium-MW oat β-glucan (4M, n = 50)
Number of subjects: 367
Study 22118569 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g medium-MW oat β-glucan (3M, n = 54)
Number of subjects: 367
Study 22118569 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g low-MW oat β-glucan (4L, n = 51)
Number of subjects: 367
Study 19797553 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing
Number of subjects: 194
Study 19797553 — intervention group
Group type: COMPARATOR
Intervention: Single-tooth extraction with placebo
Number of subjects: 194
Study 17022023 — intervention group
Group type: EXPERIMENTAL
Intervention: History of infertility (physician diagnosis, prescription for infertility medication, or evaluation at infertility clinics)
Number of subjects: 18
Study 17022023 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription of clomiphene citrate within 60 days before to 15 days after conception
Number of subjects: 18
Study 17022023 — intervention group
Group type: COMPARATOR
Intervention: Control group (no history of infertility)
Number of subjects: 18
Study 17022023 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prescription of clomiphene citrate)
Number of subjects: 18
Study 15163330 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional programme (12 mg/day iron and 6000 IU/week vitamin A)
Number of subjects: 102
Study 15163330 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone therapy (5 mg/day for 6 months)
Number of subjects: 102
Study 15163330 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone depot (100 mg monthly for 3 months or 6 months)
Number of subjects: 102
Study 15163330 — intervention group
Group type: COMPARATOR
Intervention: Passive observation
Number of subjects: 102
Study 11343496 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary structured breastfeeding counseling (SSBC)
Number of subjects: 0
Study 11343496 — intervention group
Group type: COMPARATOR
Intervention: Conventional hospital breastfeeding support (CHBS)
Number of subjects: 0
Study 9404208 — intervention group
Group type: EXPERIMENTAL
Intervention: AUTOKV mode (automatic kV selection)
Number of subjects: 0
Study 9404208 — intervention group
Group type: COMPARATOR
Intervention: Fixed kV of 28
Number of subjects: 0
Study 8093915 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 3809
Study 8093915 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin (SH)
Number of subjects: 3809
Study 2889306 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion of SMS 201-995 (50 micrograms and 100 micrograms a day)
Number of subjects: 7
Study 2889306 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion of SMS 201-995 (100 micrograms)
Number of subjects: 7
Study 2889306 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion of SMS 201-995
Number of subjects: 7
Study 2889306 — intervention group
Group type: COMPARATOR
Intervention: Multiple subcutaneous injections of SMS 201-995 (100 micrograms each)
Number of subjects: 7
Study 29771337 — intervention group
Group type: EXPERIMENTAL
Intervention: SCP+PCP (Survivorship Care Plans taken to Primary Care Physician)
Number of subjects: 96
Study 29771337 — intervention group
Group type: COMPARATOR
Intervention: SC (Survivorship Clinic)
Number of subjects: 96
Study 29771337 — intervention group
Group type: EXPERIMENTAL
Intervention: SCP+PCP
Number of subjects: 96
Study 29771337 — intervention group
Group type: COMPARATOR
Intervention: SC
Number of subjects: 96
Study 27351628 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (4.5 mg/m2/day, titrated to a target blood trough of 5-15 ng/mL)
Number of subjects: 111
Study 27351628 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 111
Study 24100337 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4
Number of subjects: 40
Study 24100337 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 40
Study 22715833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold air application
Number of subjects: 40
Study 22715833 — intervention group
Group type: COMPARATOR
Intervention: No cold air application
Number of subjects: 40
Study 22715833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold air application in palm injections
Number of subjects: 40
Study 20501394 — intervention group
Group type: EXPERIMENTAL
Intervention: BUMA drug-eluting stent
Number of subjects: 22
Study 20501394 — intervention group
Group type: COMPARATOR
Intervention: Endeavor drug-eluting stent
Number of subjects: 22
Study 18703460 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-session female condom skills training intervention
Number of subjects: 409
Study 18703460 — intervention group
Group type: COMPARATOR
Intervention: 4-session women's general health promotion intervention
Number of subjects: 409
Study 15852992 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide
Number of subjects: 45
Study 15852992 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg metoclopramide
Number of subjects: 45
Study 15852992 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 45
Study 11863320 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg
Number of subjects: 60
Study 11863320 — intervention group
Group type: COMPARATOR
Intervention: ondansetron 4 mg
Number of subjects: 60
Study 9771858 — intervention group
Group type: EXPERIMENTAL
Intervention: High nonstarch polysaccharide (NSP) diet
Number of subjects: 12
Study 9771858 — intervention group
Group type: COMPARATOR
Intervention: Usual mixed diet
Number of subjects: 12
Study 7826816 — intervention group
Group type: EXPERIMENTAL
Intervention: CRC patients
Number of subjects: 185
Study 7826816 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 185
Study 3063436 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg sodium hyaluronate
Number of subjects: 63
Study 3063436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 30077383 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant placement with ultra-wide 7-mm-diameter implants
Number of subjects: 0
Study 30077383 — intervention group
Group type: COMPARATOR
Intervention: Delayed implant placement in molar healed sites after socket preservation
Number of subjects: 0
Study 27068423 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal inferior turbinoplasty
Number of subjects: 60
Study 27068423 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency cauterization
Number of subjects: 60
Study 27068423 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy adults)
Number of subjects: 60
Study 23899952 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial memory training program
Number of subjects: 51
Study 23899952 — intervention group
Group type: COMPARATOR
Intervention: Active control group (discussing different psychological issues)
Number of subjects: 51
Study 21492416 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (30 mg/kg/dose) administered once weekly for three doses
Number of subjects: 200
Study 21492416 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered once weekly for three doses
Number of subjects: 200
Study 16409560 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate (LC) dietary advice
Number of subjects: 102
Study 16409560 — intervention group
Group type: COMPARATOR
Intervention: Reduced-portion, low-fat dietary advice (Control)
Number of subjects: 102
Study 15232360 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib sodium 40 mg twice daily for 7 days
Number of subjects: 123
Study 15232360 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 123
Study 15232360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg 4 times daily for 5 days
Number of subjects: 123
Study 11720831 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (5000 units)
Number of subjects: 100
Study 9480237 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous delivery
Number of subjects: 50
Study 9480237 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin induced delivery
Number of subjects: 50
Study 9480237 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean section
Number of subjects: 50
Study 9480237 — intervention group
Group type: COMPARATOR
Intervention: Control (beta 2-microglobulin)
Number of subjects: 50
Study 8201970 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (IV bolus of 220 mg followed by IV infusion of 1 mg/kg/h)
Number of subjects: 20
Study 8201970 — intervention group
Group type: COMPARATOR
Intervention: NaCl (control)
Number of subjects: 20
Study 3354399 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (230 patients)
Number of subjects: 448
Study 3354399 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (218 patients)
Number of subjects: 448
Study 31218819 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily for 12 weeks
Number of subjects: 300
Study 31218819 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 12 weeks
Number of subjects: 300
Study 28337686 — intervention group
Group type: COMPARATOR
Intervention: Knowledge only
Number of subjects: 255
Study 28337686 — intervention group
Group type: COMPARATOR
Intervention: Skills only
Number of subjects: 255
Study 28337686 — intervention group
Group type: COMPARATOR
Intervention: Combined knowledge and skills (TBSI)
Number of subjects: 255
Study 28337686 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 255
Study 25596158 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace
Number of subjects: 126
Study 25596158 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 126
Study 23318399 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n=361 patients after intervention)
Number of subjects: 826
Study 23318399 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=389 patients after intervention)
Number of subjects: 826
Study 23318399 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n=402 patients before intervention)
Number of subjects: 826
Study 23318399 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=424 patients before intervention)
Number of subjects: 826
Study 21199268 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg daily
Number of subjects: 1035
Study 21199268 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (starting dose 1 mg/day, max 6 mg/day)
Number of subjects: 1035
Study 19081901 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium chloride (SR)
Number of subjects: 142
Study 19081901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142